What is new in therapy of glomerulonephritis in 2003/2004.
The article reviews reports and opinions dealing with management of human glomerulonephritis that have appeared in the years 2003/2004. The following glomerulopathies have been covered: primary focal and segmental glomerulosclerosis, IgA nephropathy, membranous nephropathy, lupus nephritis, ANCA positive vasculitis and HCV-positive membranoproliferative cryoglobulinemic glomerulopathy. Aside from original studies, expert opinions and recommendations have been cited.
Hruby
Z
Z
Department of Nephrology, Medical University of Wrocław, Voivodship Speciality Hospital, Poland. hruby@wssk.wroc.pl
D019867:Anti-Glomerular Basement Membrane Disease / Q000628:therapy; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D005921:Glomerulonephritis / Q000276:immunology / Q000628:therapy* / Q000821:virology; D005922:Glomerulonephritis, IGA / Q000628:therapy; D015432:Glomerulonephritis, Membranoproliferative / Q000628:therapy; D015433:Glomerulonephritis, Membranous / Q000628:therapy; D005923:Glomerulosclerosis, Focal Segmental / Q000628:therapy; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008181:Lupus Nephritis / Q000628:therapy; D016896:Treatment Outcome
D019268:Antibodies, Antineutrophil Cytoplasmic